Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy

Cancer Letters

Volumn 353, Issue 2, 2014, Pages 160-166

  Sullivan, Ivana ^a,b   Salazar, Juliana ^a,c   Majem, Margarita ^a   Pallarés, Cinta ^a   del Río, Elisabeth ^a,b   Páez, David ^a   Baiget, Montserrat ^a,c   Barnadas, Agustí ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

DNA repair; Non small cell lung cancer; Platinum based chemotherapy; Radiotherapy; Single nucleotide polymorphisms

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DNA; GEMCITABINE; NAVELBINE; PEMETREXED; TAXANE DERIVATIVE; DNA BINDING PROTEIN; DNA HELICASE; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; ERCC2 PROTEIN, HUMAN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XERODERMA PIGMENTOSUM GROUP F PROTEIN; XPBC ERCC 3 PROTEIN; XPBC-ERCC-3 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER MODEL; CONTROLLED STUDY; DNA REPAIR; DRUG RESPONSE; ERCC1 GENE; ERCC2 GENE; ERCC3 GENE; ERCC4 GENE; ERCC5 GENE; FEMALE; GASTROINTESTINAL TOXICITY; GENE; GENETIC VARIABILITY; HUMAN; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION INJURY; RADIATION PNEUMONIA; SINGLE NUCLEOTIDE POLYMORPHISM; XPA GENE; XRCC1 GENE; XRCC2 GENE; DISEASE FREE SURVIVAL; GENETIC ASSOCIATION; GENETICS; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MIDDLE AGED; MORTALITY; NON-SMALL CELL LUNG CANCER; PATHOLOGY; PLATINUM-BASED CHEMOTHERAPY; RADIOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISMS; TREATMENT OUTCOME; VERY ELDERLY;

DNA REPAIR; NON-SMALL CELL LUNG CANCER; PLATINUM-BASED CHEMOTHERAPY; RADIOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISMS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DNA HELICASES; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84908663193     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.023     Document Type: Article

References (25)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N. Engl. J. Med 2008, 359:1367-1380.
3. Goffin J., Lacchetti C., Ellis P.M., et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J. Thorac. Oncol 2010, 5:260-274.
4. Rosenberg B., Vancamp L., Trosko J., et al. Platinum compounds: a new class of potent antitumour agents. Nature 1969, 222:385-386.
5. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev 1998, 24:331-344.
6. Martin L., Hamilton T., Schilder R. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res 2008, 14:1291-1295.
7. Simon G., Khan R., Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int. J. Biochem. Cell Biol 2007, 39:1318-1328.
8. Giovannetti E., Toffalorio F., De Pas T., et al. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?. Pharmacogenomics 2012, 13:1073-1086.
9. Yin J.Y., Huang Q., Zhao Y.C., et al. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS ONE 2012, 7:e38150.
10. Hildebrandt M.A., Gu J., Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin. Drug Metab. Toxicol 2009, 5:745-755.
11. Bonanno L., Favaretto A., Rosell R. Platinum drugs and DNA repair mechanisms in lung cancer. Anticancer Res 2014, 34:493-501.
12. AJCC Cancer Staging Manual 2010, Springer, New York, NY. seventh ed. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.)
13. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45:228-247.
14. U.S. Department of Health and Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010).
15. Cox J.D, Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys 1995, 31:1341-1346.
16. Boyle A.P., Hong E.L., Hariharan M., et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012, 22:1790-1797.
17. Akaike H. A new look at the statistical model identification. IEEE Trans. Autom. Control 1974, AC-19:716-723.
18. Horgan A.M., Yang B., Azad A.K., et al. Pharmacogenetic and germline prognostic markers of lung cancer. J. Thorac. Oncol 2011, 6:296-304.
19. Wei S.Z., Zhan P., Shi M.Q., et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med. Oncol 2011, 28:315-321.
20. Ludovini V., Floriani I., Pistola L., et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J. Thorac. Oncol 2011, 6:2018-2026.
21. Ren S., Zhou S., Wu F., et al. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer 2012, 75:102-109.
22. Joerger M., Burgers S.A., Baas P., et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2012, 118:2466-2475.
23. Yu J.J., Lee K.B., Mu C., et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol 2000, 16:555-560.
24. Lunn R.M., Helzlsouer K.J., Parshad R., et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000, 21:551-555.
25. Rosell R., Taron M., Ariza A., et al. Molecular predictors of response to chemotherapy in lung cancer. Semin. Oncol 2004, 31:20-27.